CMO/CDMO Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

CMO/CDMO Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global CMO/CDMO biotechnology market is experiencing unprecedented growth over the next decade. The market's revenue is set to soar from US$ 13 billion in 2024 to an estimated US$ 32 billion by the end of 2031. This remarkable growth is attributed to innovations in biologic manufacturing, increased adoption of contract manufacturing and development services, and expanding opportunities in emerging markets.

Rising Demand for Stand-Alone Services

Throughout the forecast period, the demand for stand-alone services is expected to remain the highest. Contract development and manufacturing organizations (CDMOs) provide critical services to biotechnology and biopharmaceutical companies, encompassing bio-manufacturing, analytical testing, development, clinical supply, fill-finishing, packaging, and more. Stand-alone services hold the largest market share, driven by the expanding cell-line development services in biopharmaceutical and biotechnology industries, accounting for 62.2% of the market.

Technological Advancements and Operational Efficiency

Leading CDMOs are focused on increasing manufacturing capacity while maintaining operational speed and flexibility. Cutting-edge single-use technologies have enabled companies to reduce batch manufacturing and cleaning time significantly. This operational efficiency provides a competitive edge and supports the industry's growth.

Market Growth Drivers

1. Novel Biologic and Biosimilar Manufacturing: The manufacturing of novel biologics and biosimilars offers substantial growth potential for the CMO/CDMO biotechnology market. Scientific advancements in biopharmaceuticals create opportunities for technologically enhanced CDMOs.

2. Adoption of CMO/CDMO Business Models: The adoption of CMO and CDMO business models, along with a focus on reducing operational costs, is driving market growth. Outsourcing R&D and commercialization of biopharmaceuticals to CMOs/CDMOs can enhance operational efficiency.

3. High Costs and Talent Gap: However, the market faces challenges related to the high costs associated with contract manufacturing investments. Additionally, the shortage of highly qualified and experienced professionals hampers growth in some regions.

Booming U.S. Market

The U.S. market is experiencing robust growth due to ongoing merger and acquisition activities among American manufacturers. The preference for single-use bioreactors is on the rise in the biopharmaceutical CDMOs market, supporting the growth of the industry.

Lucrative Prospects in the U.K.

The United Kingdom is expected to become a lucrative market due to expanding applications in gene and cell therapy. Manufacturers in the U.K. are providing top-notch biopharmaceutical contract development and manufacturing services, focusing on global presence and technological capabilities.

South Korea's Emerging Prominence

South Korea is emerging as a prominent market in East Asia, primarily due to its comprehensive range of developmental services, including cell line creation, process development, and formulation analysis methodology.

Competitive Landscape

Key players in the CMO/CDMO biotechnology market are expanding their presence in emerging regions and introducing new products. They are also strengthening their distribution channels, including online sources of advertisement.

Key Companies Profiled:
• Patheon N.V.
• Catalent
• Samsung Biologics Co., Ltd
• Lonza
• Boehringer Ingelheim
• Samsung BioLogics
• AGC Biologics, Inc.
• WuXi Biologics
• AbbVie Inc
• Avid Bioservices, Inc.
• Fujifilm Diosynth Biotechnologies
• Xpress Biologic
• Rentschler Biopharma SE
• KBI Biopharma (JSR Corporation)
• Cytovance Biologics

The CMO/CDMO biotechnology market is poised for substantial growth, driven by technological advancements and the expansion of contract manufacturing and development services. As the industry continues to evolve, these services will play a pivotal role in accelerating the development and production of biopharmaceuticals and biosimilars.

Market Segmentation

By Service:
• Stand-Alone Services
Cell-line development
Development and Bio manufacturing
Analytical Services
Fill Finish
Packaging
Clinical Supply Services
• Integrated

By Product:
• Monoclonal Antibodies
• Antibody Fragments
• Recombinant Therapeutic Proteins
• Viral Vector
• Cell and Gene Therapy
• Vaccine

By Expression System:
• Mammalian
• Microbial
Bacteria
Yeast

By Company Size:
• Small
• Mid-Sized
• Large
• Very Large

By Scale of Operations:
• Pre-clinical
• Clinical
• Commercial

By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.